title: 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience.
abstract: BACKGROUND
  The use of left ventricular assist devices (LVADs) as bridge to transplantation is now accepted as a standard of care for a subset of end-stage heart failure patients. Our interim experience with both pneumatically and electrically powered ThermoCardiosystems LVADs is presented to outline the benefits and limitations of device support as well as discuss its potential role as bridge to recovery and as destination therapy.
  
  
  RESULTS
  Detailed records were kept prospectively for all patients undergoing LVAD insertion. One hundred LVADs were inserted over 7 years into 95 patients, with an overall survival rate of 75% and a transplantation rate of 70%. Four patients underwent device explant for recovered myocardial function. Three patients received LVADs as destination therapy in the ongoing REMATCH (Randomized Evaluation of Mechanical Assist Treatment for Congestive Heart failure) trial. Overall mean patient age was 51 years, and mean duration of support was 108 days. There were 25 device-related infections including the drive line, device pocket, and blood-contacting surfaces. Cerebral vascular accidents and other embolic events occurred in 7 patients with six deaths. There were four device malfunctions and nine graft-related hemorrhages, resulting in six reoperations and three deaths.
  
  
  CONCLUSIONS
  The use of long-term implantable LVADs will likely not be limited to bridge to transplantation. The REMATCH trial has commenced to study the role LVADs may have as an alternative to medical management. Furthermore, as the issues of myocardial recovery are examined, the "bridge to recovery" may be an important additional role for these assist devices.
authors.affiliation: Department of Surgery, Columbia Presbyterian Medical Center, New York, New York, USA. bcsun@psghs.edu
authors.forename: B C
authors.initials: BC
authors.lastname: Sun
authors.forename: K A
authors.initials: KA
authors.lastname: Catanese
authors.forename: T B
authors.initials: TB
authors.lastname: Spanier
authors.forename: M R
authors.initials: MR
authors.lastname: Flannery
authors.forename: M T
authors.initials: MT
authors.lastname: Gardocki
authors.forename: L S
authors.initials: LS
authors.lastname: Marcus
authors.forename: H R
authors.initials: HR
authors.lastname: Levin
authors.forename: E A
authors.initials: EA
authors.lastname: Rose
authors.forename: M C
authors.initials: MC
authors.lastname: Oz
mesh_terms: D002423:Cause of Death; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D016027:Heart Transplantation; D006353:Heart-Assist Devices; D017052:Hospital Mortality; D006785:Hospitals, University; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009519:New York City; D015996:Survival Rate